Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
ID05677880

Unraveling the Early Phases of Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)

Led by University of Wisconsin, Madison · Updated on 2026-01-15

660

Participants Needed

12

Research Sites

8 weeks

Total Duration

On this page

Sponsors

U

University of Wisconsin, Madison

Lead Sponsor

N

National Institute on Aging (NIA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), a common inherited vascular dementia that leads to vascular cognitive impairment and dementia (VCID). This observational study aims to understand the risk factors and progression of CADASIL by examining biological, imaging, and clinical changes from early to symptomatic stages. The study will enroll 575 participants with a family history of CADASIL who have undergone genetic testing for a NOTCH3 variant. Participants will be grouped based on their genetic status and symptoms: healthy family members without the NOTCH3 mutation, pre-symptomatic members with the mutation, symptomatic members without functional decline, and symptomatic members with early dementia signs. The study involves no drug treatment but includes clinical interviews, neurological exams, neurocognitive and behavioral assessments, MRI scans, and blood draws. There will be three in-person visits at baseline, 18 months, and 36 months, with additional remote contacts as needed. During the study, participants will complete evaluations to measure cognitive function, brain volume, brain connectivity, and biomarkers like Neurofilament Light. The researchers will track changes over 36 months and assess disability and disease severity scores. Participants will be monitored through clinical exams, imaging, and questionnaires, with a total commitment of up to five years. The study aims to gather detailed information on CADASIL progression and factors influencing outcomes.

CONDITIONS

Brief Title

Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Must be at least 18 years old
  • Positive NOTCH3 genetic testing, positive skin biopsy, or willingness to have a NOTCH3 genetic test before enrolling
  • At-risk for or clinically diagnosed with CADASIL
  • Willing to commit to three in-person visits: baseline, 18 months, and 36 months, plus remote visits as needed
  • Willing to provide documentation of all current medications throughout the study
  • Willing and able to undergo MRI scans and blood draws at each in-person visit
  • Must have a designated study companion who knows the participant well and can provide additional information
  • Functional capacity less than 4 on the Modified Rankin Scale
  • Healthy controls must meet the same criteria except have negative NOTCH3 genetic testing
Not Eligible

You will not qualify if you...

  • History of severe learning disability, intellectual disability, or neurological disease unrelated to CADASIL
  • History of serious alcohol or drug abuse within the past year
  • Unwilling to undergo NOTCH3 genetic testing if no test is on file

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - 36 months

Participants complete neurocognitive tests, clinical interviews, neurological exams, MRI scans, and blood draws to assess their cognitive and neurological status.

3 in-person visits at baseline, 18 months, and 36 months, plus remote visits as needed

Long-term Monitoring

Duration - 36 months

Participants are monitored over time to track changes in brain structure, cognitive function, and biomarkers related to CADASIL.

Remote visits as needed throughout the study

Trial Site Locations

Total: 12 locations

1

University of California

Los Angeles, California, United States, 90095

Actively Recruiting

2

University of California

San Francisco, California, United States, 94143

Actively Recruiting

3

University of Colorado

Denver, Colorado, United States, 80204

Actively Recruiting

4

Georgia State University Research Foundation

Atlanta, Georgia, United States, 30303

Actively Recruiting

5

Loyola University

Chicago, Illinois, United States, 60660

Actively Recruiting

6

Columbia University

New York, New York, United States, 10027

Actively Recruiting

7

Oregon Health & Science University

Portland, Oregon, United States, 97239

Actively Recruiting

8

Brown University

Providence, Rhode Island, United States, 02912

Actively Recruiting

9

University of Texas Health Science Center

Houston, Texas, United States, 77030

Not Yet Recruiting

10

University of Texas

San Antonio, Texas, United States, 78249

Not Yet Recruiting

11

University of Utah

Salt Lake City, Utah, United States, 84112

Actively Recruiting

12

University of Washington

Seattle, Washington, United States, 98195

Actively Recruiting

Loading map...

Research Team

C

Cadasil Consortium

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

4

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here